Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$15.43 +0.2%	$13.98	$7.86 ▼ $17.75	$1.84B	1.77	2.14 million shs	1.77 million shs
OCUL Ocular Therapeutix	$11.25 +1.4%	$8.64	$5.79 ▼ $11.78	$1.77B	1.43	1.43 million shs	2.12 million shs
SIGA Siga Technologies	$6.78 +1.2%	$6.29	$4.95 ▼ $12.83	$478.66M	0.94	712,115 shs	221,368 shs
SRPT Sarepta Therapeutics	$18.38 +0.9%	$29.15	$16.88 ▼ $150.48	$1.79B	0.45	2.31 million shs	12.02 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+0.19%	+8.51%	+15.15%	+18.60%	+44.61%
OCUL Ocular Therapeutix	+1.44%	+4.55%	+28.57%	+53.90%	+33.93%
SIGA Siga Technologies	+1.19%	-1.74%	+4.31%	+13.19%	-26.94%
SRPT Sarepta Therapeutics	+0.93%	-5.11%	-12.23%	-65.83%	-87.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	1.2646 of 5 stars	2.4	1.0	0.0	2.5	1.7	0.6
OCUL Ocular Therapeutix	3.8832 of 5 stars	3.5	2.0	4.1	2.2	2.5	0.0
SIGA Siga Technologies	2.2206 of 5 stars	0.0	3.0	0.0	2.0	0.8	3.1
SRPT Sarepta Therapeutics	4.7294 of 5 stars	4.2	2.0	4.2	2.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	21.84% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	54.07% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
SRPT Sarepta Therapeutics	2.44	Hold	$58.54	218.51% Upside

Current Analyst Ratings Breakdown

Latest SIGA, ARQT, SRPT, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	9.36	N/A	N/A	$1.35 per share	11.43
OCUL Ocular Therapeutix	$63.72M	28.13	N/A	N/A	$2.01 per share	5.60
SIGA Siga Technologies	$120.33M	4.03	$0.85 per share	8.01	$3.02 per share	2.25
SRPT Sarepta Therapeutics	$1.90B	0.95	$2.46 per share	7.48	$15.99 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$1.04	N/A	N/A	N/A	-60.95%	-80.66%	-32.94%	8/13/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	10.12	5.42	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.68	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest SIGA, ARQT, SRPT, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.19	N/A	N/A	N/A	$72.70 million	N/A
8/6/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	N/A	N/A	N/A	$13.12 million	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.75	3.55	3.37
OCUL Ocular Therapeutix	0.26	10.22	10.14
SIGA Siga Technologies	N/A	8.40	6.28
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
OCUL Ocular Therapeutix	59.21%
SIGA Siga Technologies	55.40%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
OCUL Ocular Therapeutix	2.30%
SIGA Siga Technologies	1.95%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	108.00 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

SIGA, ARQT, SRPT, and OCUL Headlines

Recent News About These Companies

Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths

1 hour ago | genengnews.comG

Positive Outlook for Sarepta Therapeutics Amid Strategic Restructuring and Regulatory Resolution

1 hour ago | tipranks.com

Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box' Warning Are Good News.

2 hours ago | barrons.com

Sarepta: Finally, A Little Relief For Bulls; I Expect More

2 hours ago | seekingalpha.com

Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan

July 16 at 11:52 PM | msn.com

Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult

July 16 at 11:52 PM | msn.com

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

July 16 at 7:53 PM | globenewswire.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SRPT

July 16 at 6:50 PM | theglobeandmail.com

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

July 16 at 6:50 PM | bostonglobe.comB

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

July 16 at 6:50 PM | biopharmadive.comB

Sarepta Therapeutics makes layoffs after gene therapy setback

July 16 at 6:50 PM | bizjournals.com

JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating

July 16 at 6:50 PM | msn.com

Sarepta Therapeutics stock soars after strategic restructuring plan unveiled

July 16 at 6:50 PM | investing.com

Sarepta to cut 500 jobs after gene therapy setback, shares jump

July 16 at 6:50 PM | msn.com

Sarepta Therapeutics to Restructure, Lay Off 500 Workers

July 16 at 6:50 PM | msn.com

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

July 16 at 6:50 PM | finance.yahoo.com

Sarepta Therapeutics rises after restructuring, pipeline focus

July 16 at 6:50 PM | msn.com

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

July 16 at 5:49 PM | benzinga.com

Sarepta Therapeutics (SRPT) Reports Q2 SG&A Expenses | SRPT Stock News

July 16 at 4:42 PM | gurufocus.com

Sarepta to cut 500 jobs after gene therapy setback

July 16 at 4:21 PM | reuters.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.7% - Should You Buy?

July 14 at 12:30 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA, ARQT, SRPT, and OCUL Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$15.43 +0.03 (+0.19%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$15.30 -0.13 (-0.81%)

As of 07:06 AM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Ocular Therapeutix NASDAQ:OCUL

$11.25 +0.16 (+1.44%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$11.09 -0.16 (-1.41%)

As of 07:00 AM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Siga Technologies NASDAQ:SIGA

$6.78 +0.08 (+1.19%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$6.80 +0.01 (+0.22%)

As of 07:10 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Sarepta Therapeutics NASDAQ:SRPT

$18.38 +0.17 (+0.93%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$24.69 +6.31 (+34.34%)

As of 07:16 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time